Annual report pursuant to Section 13 and 15(d)

Acquisition - Narrative (Details)

v3.8.0.1
Acquisition - Narrative (Details) - USD ($)
 1 Months Ended
Nov. 17, 2017
Dec. 31, 2017
Dec. 31, 2016
Business Acquisition [Line Items]      
Goodwill   $ 14,292,282 $ 0
TRx      
Business Acquisition [Line Items]      
Cash $ 18,900,000    
Unregistered shares of common stock issued or issuable as part of acquisition (in shares) 7,534,884    
Shares issued for purchase of business $ 8,500,000    
Shares issued upon closing (in shares) 5,184,920    
Contingent shares issuable as part of acquisition (in shares) 2,349,968    
Goodwill $ 14,292,282    
Goodwill, expected tax deductible amount $ 9,200,000    
Adjustment to inventory   200,000  
Cost of Sales | TRx      
Business Acquisition [Line Items]      
Adjustment to inventory   $ 138,000  
PAI Sales & Marketing Agreement | TRx      
Business Acquisition [Line Items]      
Acquired finite-lived intangible assets, weighted average useful life (in years) 2 years    
Metafolin | Acquired product marketing rights | TRx      
Business Acquisition [Line Items]      
Acquired finite-lived intangible assets, weighted average useful life (in years) 15 years    
Millipred | Acquired product marketing rights | TRx      
Business Acquisition [Line Items]      
Acquired finite-lived intangible assets, weighted average useful life (in years) 4 years    
Ulesfia | Acquired product marketing rights | TRx      
Business Acquisition [Line Items]      
Acquired finite-lived intangible assets, weighted average useful life (in years) 3 years